Literature DB >> 23182994

Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.

Hans M Westgeest1, Nielka P van Erp, Richard J Honeywell, Ronald Hoekstra, Godefridus J Peters, Henk M W Verheul.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23182994     DOI: 10.1200/JCO.2012.43.6485

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

2.  Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.

Authors:  Kristy J Gotink; Maria Rovithi; Richard R de Haas; Richard J Honeywell; Henk Dekker; Dennis Poel; Kaamar Azijli; Godefridus J Peters; Henk J Broxterman; Henk M W Verheul
Journal:  Cell Oncol (Dordr)       Date:  2015-02-11       Impact factor: 6.730

3.  Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance.

Authors:  Richard J Honeywell; Ietje Kathmann; Elisa Giovannetti; Carmelo Tibaldi; Egbert F Smit; Maria N Rovithi; Henk M W Verheul; Godefridus J Peters
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

Review 4.  Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.

Authors:  Hana Studentova; Jindriska Volakova; Martina Spisarova; Anezka Zemankova; Kvetoslava Aiglova; Tomas Szotkowski; Bohuslav Melichar
Journal:  BMC Gastroenterol       Date:  2022-02-05       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.